Korean Aesthetics Companies Target US Medspas to Treat GLP-1 Volume Loss

On August 9, 2026, South Korean medical aesthetics companies accelerated their push into the United States medspa market, capitalizing on the rising clinical demand for treatments that address facial volume loss caused by GLP-1 weight-loss drugs like Ozempic, Wegovy, and Mounjaro. This strategic expansion brings new product pipelines and substantial corporate backing directly to US providers. For instance, PharmaResearch, the manufacturer of the popular polynucleotide treatment Rejuran, has partnered with the major United States medspa chain LaserAway to secure a direct clinical footprint. Concurrently, South Korean toxin and filler manufacturer Hugel has appointed industry veteran Carrie Strom as its global CEO to drive its expansion in the United States. For independent clinic owners, this targeted corporate push means a wider array of imported skin quality and regenerative options. As these major Korean brands build out their domestic distribution networks and consumer marketing, patients will likely begin asking for Rejuran and similar treatments by name, making it highly practical to evaluate how these emerging regenerative protocols complement your existing device and filler offerings.

Source: KED Global, https://www.kedglobal.com/beauty-cosmetics/newsView/ked202608090001